ClinConnect ClinConnect Logo
Search / Trial NCT00812084

Costs, Health Status and Outcomes of CAP (Community-Acquired Pneumonia)

Launched by UMC UTRECHT · Dec 18, 2008

Trial Information

Current as of June 08, 2025

Completed

Keywords

Quality Of Life Health Resources Costs Community Acquired Pneumonia

ClinConnect Summary

Within the study data on quality of life and various health and non-health resources and their costs is collected with the help of questionnaires administered at different points in time in different cohorts. Data collection is additional upon data collected in the main CAPITA trial, such as incidence data, mortality estimates, use of some health care resources, vaccine effectiveness and general background (socio-demographic) data.

In a first sub-study of CHO-CAP, the CAPITA participants are asked, via written information distributed shortly after vaccination, to fill in once-only a short ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Only participants of the CAPITA trial. Therefore the inclusion criteria as applied in CAPITA are the baseline for the current study. Additionally all participants had to be consent and had to fill in a baseline EQ-5D questionnaire
  • Additionally for CAP patients: Consent to be filling to participate as a CAP and the presence of CAP has to be confirmed by the independent adjudication committee of the main CAPITA trial
  • Additionally for controls: Consent to be filling to participate as control
  • Exclusion Criteria:
  • The non-availability of a baseline EQ-5D score is an exclusion criterion for the prospectively followed cohorts (both CAP patients and controls)
  • In all stages of the study, patients have the right to withdraw their consent and stop their participation in this study.

About Umc Utrecht

UMC Utrecht is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research and high-quality patient care. As a prominent sponsor of clinical trials, UMC Utrecht leverages its extensive expertise in translational medicine and collaboration with various stakeholders to advance medical knowledge and improve therapeutic outcomes. The institution emphasizes ethical conduct and rigorous scientific standards, ensuring that all research activities contribute meaningfully to the global healthcare landscape. Through its robust clinical trial infrastructure, UMC Utrecht plays a vital role in facilitating the development of new treatments and enhancing patient wellbeing.

Locations

The Netherlands, , Netherlands

Patients applied

0 patients applied

Trial Officials

G.Ardine de Wit, PhD

Principal Investigator

Julius Center for Health Sciences and Primary Care; UMC Utrecht

Marc J.M. Bonten, Prof., MD PhD

Principal Investigator

Julius Center for Health Sciences and Primary Care; UMC Utrecht

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials